Business Wire News with Multimedia: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease

Business Wire News with Multimedia News with Multimedia distributed by Business Wire

Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease Jul 31st 2013, 02:13 TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis. ASP1517/FG-4592, an orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), is the most clinically advanced candidate in this new class of potential anemia t Media files: astellas_logo.jpg (image/jpeg, 0 MB)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions